Medical News Hubb
Advertisement
  • Home
  • News
  • Pharmaceutical
  • Medicines & Healthy Lifestyle
  • Contact us
No Result
View All Result
  • Home
  • News
  • Pharmaceutical
  • Medicines & Healthy Lifestyle
  • Contact us
No Result
View All Result
Medical News Hubb
No Result
View All Result
Home Pharmaceutical

Medical Bulletin 23/December/2022

admin by admin
December 23, 2022
in Pharmaceutical


Sotorasib achieved clinically meaningful activity in KRAS G12C-mutated advanced pancreatic cancer

The KRAS protein is part of a normal signaling pathway regulating growth and proliferation of cells, but activating mutations in KRAS drives abnormal growth in cancer. KRAS mutations are especially common in pancreatic cancers, occurring in about 90% of patients, while KRAS G12C mutations are present in 1-2% of cases.

In the Phase I/II CodeBreaK 100 trial, the KRAS G12C inhibitor sotorasib achieved meaningful anticancer activity with an acceptable safety profile in heavily pretreated patients with KRAS G12C-mutated metastatic pancreatic cancer, according to researchers at The University of Texas MD Anderson Cancer Center.

Reference:

David S. Hong et al,Sotorasib in KRAS p.G12C–Mutated Advanced Pancreatic Cancer, New England Journal of Medicine

Breakthrough for Artemis-SCID patients in the form of Infant gene therapy

Gene correction has been used before in patients with other genetic forms of SCID, but its use in Artemis-SCID is significant because these patients usually respond more poorly to standard bone marrow transplants. Complications can include rejecting the marrow graft, graft-vs.-host disease – in which the donor T cells attack the recipient’s tissues – chronic infections leading to organ damage, stunted growth, and premature death.

Ten young children born without functioning immune systems and lacking the ability to fight infections are on track for healthier lives thanks to a new gene therapy treatment pioneered at UC San Francisco, reports a Dec. 22 study in the New England Journal of Medicine.

Reference:

Mort Cowan et al, UNIVERSITY OF CALIFORNIA – SAN FRANCISCO,JOURNAL New England Journal of Medicine

People with hand osteoarthritis may benefit from talarozole

More than 40% of individuals will develop osteoarthritis (OA) during their lifetime. Hand (OA) is an extremely common form of OA and there are currently no disease modifying treatments that effectively relieve symptoms or stop deformity and stiffness of the joints.

Tonia Vincent, Professor of Musculoskeletal Biology & Honorary Rheumatologist at Oxford’s Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), said: ‘Hand osteoarthritis is a common and debilitating medical condition that affects mainly women, especially around the time of the menopause. We currently have no effective treatments that modify their disease.’

Reference:

Tonia Vincent et al, Variants in ALDH1A2[Q1] reveal an anti-inflammatory role for retinoic acid and a new class of disease-modifying drugs in osteoarthritis ,JOURNAL Science Translational Medicine.



Source link

Tags: ArtemisArtemis SCID patientsbonebone diseasesbone marrow transplantationcancercancer researchcell therapieschildrendrug researchgene therapyhand osteoarthritishealthcarehospitalsimmune systemimmunityJournal Science Translational MedicineKRASKRAS G12CKRAS G12C mutationsNew England Journal of MedicineOAosteoarthritispancreatic cancerpediatricsSCIDSotorasibstem cell researchT celltalarozole
Previous Post

Pandemic response gets a permanent home at the White House

Next Post

FDA Approves First-in-Class Drug for Follicular Lymphoma

Next Post

FDA Approves First-in-Class Drug for Follicular Lymphoma

Recommended

A wave of overdoses is hitting an already vulnerable population

January 2, 2023

Managing Short Bowel Syndrome: Expert Review

September 12, 2022

Don't miss it

Pharmaceutical

Amgen pricing for Humira biosimilar may not help patients

January 31, 2023
Medicines & Healthy Lifestyle

Vitamin B1 Is Vital to Protect Against Infectious Disease

January 31, 2023
Medicines & Healthy Lifestyle

Orserdu Approved for ER+, HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer

January 31, 2023
Medicines & Healthy Lifestyle

First-Of-Its-Kind $1 Glove Can Detect Fetal Positions To Aid Precarious Births

January 31, 2023
News

Cardioprotection for 20 Years for Children With Cancer

January 31, 2023
Pharmaceutical

Health Bulletin 31/January/2023

January 31, 2023

© 2022 Medical News Hubb All rights reserved.

Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Privacy Policy and Terms & Conditions.

Navigate Site

  • Home
  • News
  • Pharmaceutical
  • Medicines & Healthy Lifestyle
  • Contact us

Newsletter Sign Up

No Result
View All Result
  • Home
  • News
  • Pharmaceutical
  • Medicines & Healthy Lifestyle
  • Contact us

© 2022 Medical News Hubb All rights reserved.